Effect of LSD on Renal Function in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorNorthern Jiangsu People's Hospital

About this trial

Patients with liver cirrhosis often have impaired or at-risk kidney function due to the close link between liver and kidney (hepatorenal syndrome). Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on kidney function over 2 years is unclear. This study will follow patients undergoing laparoscopic splenectomy to measure changes in kidney function before and after surgery, identify risk factors for kidney damage and whether LSD can improve kidney function in the long term, and help improve care to protect kidney function in cirrhotic patients .

Eligibility criteria

Qualifiers

Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)

Splenomegaly and hypersplenism

History of portal hypertension bleeding (esophageal and gastric variceal bleeding )

Age 18-80 years, male or female

Disqualifiers

Child-Pugh Class C liver cirrhosis

Primary renal diseases (glomerulonephritis, polycystic kidney disease, chronic pyelonephritis, etc.)

Previous abdominal surgery precluding safe laparoscopic splenectomy and azygoportal disconnection

Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

This trial has no locations